Skip to content

HIP Fracture Accelerated Surgical TreaTment and Care TracK 2 Trial

Hip Fractures | Myocardial Injury

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    45 and up

Participation Criteria

Inclusion Criteria:

1. age ≥45 years;
2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
4. informed consent.

Exclusion Criteria:

1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;
4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
6. patients refusing consent; or
7. patients previously enrolled in HIP ATTACK-2.

Study Location

Juravinski Hospital
Juravinski Hospital
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Krysten Gregus

[email protected]
Backup Contact

Ameen Patel, MD

St. Joseph's Healthcare Hamilton
St. Joseph's Healthcare Hamilton
Hamilton, Ontario
Canada

Contact Study Team

Backup Contact

Flavia Borges, MD

Primary Contact

Abdul Rahman Muammar

[email protected]
Ottawa General Hospital
Ottawa General Hospital
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Katie Mcliquham

[email protected]
Backup Contact

Robert Feibel, MD

Victoria Hospital
Victoria Hospital
London, Ontario
Canada

Contact Study Team

Backup Contact

Reem Ansari

[email protected]
Primary Contact

Relka Bihari, MD

[email protected]
Backup Contact

Abdel Lawendy, MD

University of Alberta Hospital
University of Alberta Hospital
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Maliha Muneer

[email protected]
Backup Contact

Mike Jacka, MD

Markham Stouffville Hospital
Markham Stouffville Hospital
Markham, Ontario
Canada

Contact Study Team

Backup Contact

Steve McMahon, MD

Primary Contact

Michelle Dimas

[email protected]
Study Sponsored By
Population Health Research Institute
Participants Required
More Information
Study ID: NCT04743765